Robert Ross
President bij SURFACE ONCOLOGY, INC.
Profiel
Robert W.
Ross is an Independent Director at Xilio Therapeutics, Inc. since 2022.
He is also a Director at Obsidian Therapeutics, Inc. since 2020.
Prior to his current positions, he served as the President of Surface Oncology, Inc. from 2016 to present.
Before that, he was the Senior Vice President-Clinical Development at bluebird bio, Inc. from 2015 to 2016.
Dr. Ross completed his undergraduate studies at Stanford University and pursued graduate degrees at Harvard Medical School and Columbia University College of Physicians & Surgeons.
Actieve functies van Robert Ross
| Bedrijven | Functie | Begin |
|---|---|---|
| SURFACE ONCOLOGY, INC. | President | - |
| XILIO THERAPEUTICS, INC. | Director/Board Member | 16-06-2022 |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Director/Board Member | 03-09-2020 |
Eerdere bekende functies van Robert Ross
| Bedrijven | Functie | Einde |
|---|---|---|
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01-10-2016 |
Opleiding van Robert Ross
| Stanford University | Undergraduate Degree |
| Harvard Medical School | Graduate Degree |
| Columbia University College of Physicians & Surgeons | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
